Growth Metrics

Emergent BioSolutions (EBS) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$3.4 million.

  • Emergent BioSolutions' Cash from Investing Activities fell 10303.57% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.9 million, marking a year-over-year increase of 1960.09%. This contributed to the annual value of $125.2 million for FY2024, which is 4102.68% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Cash from Investing Activities stood at -$3.4 million, which was down 10303.57% from $17.2 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Cash from Investing Activities registered a high of $257.7 million during Q2 2023, and its lowest value of -$271.6 million during Q3 2022.
  • For the 5-year period, Emergent BioSolutions' Cash from Investing Activities averaged around -$10.2 million, with its median value being -$15.1 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 39202.9% in 2022, then soared by 90280.37% in 2023.
  • Emergent BioSolutions' Cash from Investing Activities (Quarter) stood at -$45.8 million in 2021, then increased by 0.87% to -$45.4 million in 2022, then soared by 74.89% to -$11.4 million in 2023, then skyrocketed by 350.88% to $28.6 million in 2024, then crashed by 111.89% to -$3.4 million in 2025.
  • Its Cash from Investing Activities was -$3.4 million in Q3 2025, compared to $17.2 million in Q2 2025 and $59.5 million in Q1 2025.